

Please amend claim 8 to read as follows:

8. (Amended) A composition according to claim 4 wherein the derivative of citrulline is selected from L-thiocitrulline or as an S-alkylthiocitrulline.

Please cancel claims 11, 12 and 15

Please add new claims 21 to 25 as follows

- 21 A composition according to claim 4 wherein the derivative of citrulline is S-methyl-L-thiocitrulline
- 22 A composition for the damage of the formation of new vasculature by angiogenesis comprising a combination of a vascular damaging agent that is an antibody targeted to vasculature and an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the vascular damaging agent.
- 23 A composition for the damage of the formation of new vasculature by angiogenesis comprising a combination of a vascular damaging agent that is a tubulin binding agent and an inhibitor of nitric oxide synthase in an amount sufficient to augment the effect of the vascular damaging agent.
- 24 A composition according to claim 23 wherein the vascular damaging agent is selected from N-acetylcolchicinol and its prodrugs.
- 25 A composition according to claim 23 wherein the vascular damaging agent is N-acetylcolchicinol.

REMARKS

The amended claims are set out in the Appendix showing the amendments made.

Support for new claim 21 is found in original claim 8. Support for new claims 22 to 25 can be found at the bottom of page 3 and top of page 4 of the description.

With the exception of the rejections of claims 11, 12 and 15, which are rendered moot by the deletion of these claims, the applicants respectfully travers the rejections made under 35 USC 112.

The present invention lies in the applicants' use of compounds having two different types of activity to treat diseases involving active angiogenesis. Compounds having such activity are known.

The term "vascular damaging agent" is well recognized in the art. It is clear that one